Brian Brown, PhD: Targeting the Suppressors

Years Funded: 2020-2022

Targeting Macrophages to Turn Tumors Hot and Enhance Cancer Immunotherapy
Despite some amazing successes, not all patients respond to current immunotherapies. Brian Brown, PhD, professor and associate director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai (New York, NY) is working to harness the power of gene therapy to equip a patient’s own T cells to kill immune-suppressing cells called macrophages

Read More
Joseph Fraietta, PhD: Arming CAR T Cells for the Solid Tumor Battlefield

Years Funded: 2020-2022

Metabolic Reprogramming of the CAR T Cell Epigenome
At the University of Pennsylvania Perelman School of Medicine (Philadelphia, PA), Joseph Fraietta, PhD is collaborating with Naomi Haas, MD, to overcome prostate cancer’s stubborn resistance to CAR T-cell therapy. By unlocking the epigenetic code that controls the fate and function of T-cells, this research team expects to improve the success of T -cell therapy in inducing safe, long-term remission for advanced, metastatic prostate cancer.

Read More
Stephen Gottschalk, MD: I Never Need to Ask Myself Why I’m Here

Years Funded: 2020-2022

ECM-Targeted T-Cell Therapy
Building on past research breakthroughs, Stephen Gottschalk, MD, chair of Bone Marrow Transplantation and Cellular Therapy at St. Jude Children’s Research Hospital (Memphis, TN), is moving a new approach to CAR T-cell therapy into clinical trials. Using two different gene protein biomarkers, Dr. Gottschalk expects to fortify a patient’s immune system to successfully attack and destroy sarcomas along with the blood vessels that support their growth.

Read More
Greg Michael Delgoffe, PhD: The Problem with Chemo, Radiation and Surgery

Years Funded: 2017-2019

Metabolic Reprogramming of Tumor-Specific T Cells for Immunotherapy
At the University of Pittsburgh Department of Immunology (Pittsburgh, PA), Greg Michael Delgoffe, PhD, and his team are metabolically reprogramming T cells to make them more robust and fit to fight cancer for longer periods of time.

Read More
Crystal Mackall, MD: Unleashing the Hounds

Years Funded: 2016-2019

GD2 Chimeric Antigen Receptor Therapy for Osteosarcoma
A new iteration of CAR T-cell therapy developed by Crystal Mackall, MD, at Stanford University (Stanford, CA), successfully prepares T cells to seek and destroy solid tumors that express the fatty sugar biomarker GD2. Sensitivity to the GD2 biomarker directs T cells to target solid tumors, such as neuroblastoma, osteosarcoma and diffuse intrinsic pontine glioma (DPIG), in much the same way that T cells are engineered to seek and destroy cancers that express the protein biomarker CD19.

Read More

Join the Alliance

  • This field is for validation purposes and should be left unchanged.